These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 25140039)

  • 21. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
    Chinot OL; Wick W; Mason W; Henriksson R; Saran F; Nishikawa R; Carpentier AF; Hoang-Xuan K; Kavan P; Cernea D; Brandes AA; Hilton M; Abrey L; Cloughesy T
    N Engl J Med; 2014 Feb; 370(8):709-22. PubMed ID: 24552318
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients.
    Lee EQ; Kaley TJ; Duda DG; Schiff D; Lassman AB; Wong ET; Mikkelsen T; Purow BW; Muzikansky A; Ancukiewicz M; Huse JT; Ramkissoon S; Drappatz J; Norden AD; Beroukhim R; Weiss SE; Alexander BM; McCluskey CS; Gerard M; Smith KH; Jain RK; Batchelor TT; Ligon KL; Wen PY
    Clin Cancer Res; 2015 Aug; 21(16):3610-8. PubMed ID: 25910950
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors.
    Spicer J; Irshad S; Ang JE; Enting D; Kristeleit R; Uttenreuther-Fischer M; Pemberton K; Pelling K; Schnell D; de Bono J
    Cancer Chemother Pharmacol; 2017 Jan; 79(1):17-27. PubMed ID: 27872953
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck.
    Seiwert TY; Fayette J; Cupissol D; Del Campo JM; Clement PM; Hitt R; Degardin M; Zhang W; Blackman A; Ehrnrooth E; Cohen EEW
    Ann Oncol; 2014 Sep; 25(9):1813-1820. PubMed ID: 24928832
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial.
    Gállego Pérez-Larraya J; Ducray F; Chinot O; Catry-Thomas I; Taillandier L; Guillamo JS; Campello C; Monjour A; Cartalat-Carel S; Barrie M; Huchet A; Beauchesne P; Matta M; Mokhtari K; Tanguy ML; Honnorat J; Delattre JY
    J Clin Oncol; 2011 Aug; 29(22):3050-5. PubMed ID: 21709196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma.
    Penas-Prado M; Hess KR; Fisch MJ; Lagrone LW; Groves MD; Levin VA; De Groot JF; Puduvalli VK; Colman H; Volas-Redd G; Giglio P; Conrad CA; Salacz ME; Floyd JD; Loghin ME; Hsu SH; Gonzalez J; Chang EL; Woo SY; Mahajan A; Aldape KD; Yung WK; Gilbert MR; ;
    Neuro Oncol; 2015 Feb; 17(2):266-73. PubMed ID: 25239666
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab.
    Lin NU; Winer EP; Wheatley D; Carey LA; Houston S; Mendelson D; Munster P; Frakes L; Kelly S; Garcia AA; Cleator S; Uttenreuther-Fischer M; Jones H; Wind S; Vinisko R; Hickish T
    Breast Cancer Res Treat; 2012 Jun; 133(3):1057-65. PubMed ID: 22418700
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumors.
    Hiret S; Isambert N; Gomez-Roca C; Bennouna J; Sassi M; de Mont-Serrat H; Fan J; Schnell D; Delord JP
    Invest New Drugs; 2018 Dec; 36(6):1044-1059. PubMed ID: 29808308
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.
    Brada M; Hoang-Xuan K; Rampling R; Dietrich PY; Dirix LY; Macdonald D; Heimans JJ; Zonnenberg BA; Bravo-Marques JM; Henriksson R; Stupp R; Yue N; Bruner J; Dugan M; Rao S; Zaknoen S
    Ann Oncol; 2001 Feb; 12(2):259-66. PubMed ID: 11300335
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase I/II trial of vandetanib for patients with recurrent malignant glioma.
    Kreisl TN; McNeill KA; Sul J; Iwamoto FM; Shih J; Fine HA
    Neuro Oncol; 2012 Dec; 14(12):1519-26. PubMed ID: 23099652
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors.
    Awada AH; Dumez H; Hendlisz A; Wolter P; Besse-Hammer T; Uttenreuther-Fischer M; Stopfer P; Fleischer F; Piccart M; Schöffski P
    Invest New Drugs; 2013 Jun; 31(3):734-41. PubMed ID: 23161334
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide.
    Polley MY; Lamborn KR; Chang SM; Butowski N; Clarke JL; Prados M
    Neuro Oncol; 2010 Mar; 12(3):274-82. PubMed ID: 20167815
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas.
    Fields EC; Damek D; Gaspar LE; Liu AK; Kavanagh BD; Waziri A; Lillehei K; Chen C
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):51-7. PubMed ID: 21035955
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study.
    Robins HI; Zhang P; Gilbert MR; Chakravarti A; de Groot JF; Grimm SA; Wang F; Lieberman FS; Krauze A; Trotti AM; Mohile N; Kee AY; Colman H; Cavaliere R; Kesari S; Chmura SJ; Mehta M
    J Neurooncol; 2016 Jan; 126(2):309-16. PubMed ID: 26508094
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.
    Stupp R; Hegi ME; Neyns B; Goldbrunner R; Schlegel U; Clement PM; Grabenbauer GG; Ochsenbein AF; Simon M; Dietrich PY; Pietsch T; Hicking C; Tonn JC; Diserens AC; Pica A; Hermisson M; Krueger S; Picard M; Weller M
    J Clin Oncol; 2010 Jun; 28(16):2712-8. PubMed ID: 20439646
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase 2 study of dose-intense temozolomide in recurrent glioblastoma.
    Norden AD; Lesser GJ; Drappatz J; Ligon KL; Hammond SN; Lee EQ; Reardon DR; Fadul CE; Plotkin SR; Batchelor TT; Zhu JJ; Beroukhim R; Muzikansky A; Doherty L; Lafrankie D; Smith K; Tafoya V; Lis R; Stack EC; Rosenfeld MR; Wen PY
    Neuro Oncol; 2013 Jul; 15(7):930-5. PubMed ID: 23553268
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy.
    Quinn JA; Jiang SX; Reardon DA; Desjardins A; Vredenburgh JJ; Friedman AH; Sampson JH; McLendon RE; Herndon JE; Friedman HS
    J Neurooncol; 2009 Dec; 95(3):393-400. PubMed ID: 19533023
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma.
    Drappatz J; Norden AD; Wong ET; Doherty LM; Lafrankie DC; Ciampa A; Kesari S; Sceppa C; Gerard M; Phan P; Schiff D; Batchelor TT; Ligon KL; Young G; Muzikansky A; Weiss SE; Wen PY
    Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):85-90. PubMed ID: 20137866
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer.
    Hickish T; Cassidy J; Propper D; Chau I; Falk S; Ford H; Iveson T; Braun M; Potter V; Macpherson IR; Finnigan H; Lee C; Jones H; Harrison M
    Eur J Cancer; 2014 Dec; 50(18):3136-44. PubMed ID: 25441408
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma.
    Clarke JL; Iwamoto FM; Sul J; Panageas K; Lassman AB; DeAngelis LM; Hormigo A; Nolan CP; Gavrilovic I; Karimi S; Abrey LE
    J Clin Oncol; 2009 Aug; 27(23):3861-7. PubMed ID: 19506159
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.